Medicure Inc Total Assets

Latest as of June 2026: CA$22.59 Million CAD ≈ $16.34 Million USD

Medicure Inc total assets. Based on the latest financial reports, Medicure Inc (MPH) holds total assets worth CA$22.59 Million CAD (≈ $16.34 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Medicure Inc stock valuation for the company's overall valuation and market capitalisation.

Total Assets of Medicure Inc (2000–2025)

Total assets of Medicure Inc from 2000 to 2025. This chart illustrates how Medicure Inc's total assets have evolved over time, based on quarterly financial data. See MPH stock price for real-time trading data and today's change.

Medicure Inc - Asset Composition Analysis

Medicure Inc Total Assets Breakdown (December 2025)

Medicure Inc total assets breakdown as of December 2025. Medicure Inc's total assets of CA$22.59 Million consist of 47.7% current assets and 52.4% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 15.4%
Accounts Receivable CA$4.72 Million 18.9%
Inventory CA$2.94 Million 11.8%
Property, Plant & Equipment CA$0.00 0.0%
Intangible Assets CA$7.75 Million 31.1%
Goodwill CA$4.26 Million 17.1%

Asset Composition Trend (2000–2025)

This chart illustrates how Medicure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MPH working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Medicure Inc's current assets represent 47.7% of total assets in 2025, a decrease from 91.5% in 2000.
  • Cash Position: Cash and equivalents constituted 15.4% of total assets in 2025, down from 85.4% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2000.
  • Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.

Medicure Inc Competitors by Total Assets

Key competitors of Medicure Inc based on total assets are shown below.

Company Country Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
China CN¥9.54 Billion
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
China CN¥6.44 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Bide Pharmatech Co. Ltd. A
SHG:688073
China CN¥2.54 Billion
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
China CN¥4.69 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥25.73 Billion

Medicure Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.97 1.48 1.28
Quick Ratio 0.64 1.06 0.92
Cash Ratio 0.00 0.00 0.00
Working Capital CA$-336.00K CA$4.59 Million CA$3.05 Million

Medicure Inc - Advanced Valuation Insights

This section examines the relationship between Medicure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.34
Latest Market Cap to Assets Ratio 1.04
Asset Growth Rate (YoY) -15.9%
Total Assets CA$24.95 Million
Market Capitalization $25.99 Million USD

Valuation Analysis

Above Book Valuation: The market values Medicure Inc's assets above their book value (1.04x), reflecting positive investor sentiment about the company's future prospects.

Significant Asset Reduction: Medicure Inc's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Medicure Inc (2000–2025)

The table below shows the annual total assets of Medicure Inc from 2000 to 2025.

Year Total Assets Change
2025-12-31 CA$24.95 Million
≈ $18.05 Million
-15.94%
2024-12-31 CA$29.68 Million
≈ $21.47 Million
+5.77%
2023-12-31 CA$28.06 Million
≈ $20.30 Million
-6.15%
2022-12-31 CA$29.90 Million
≈ $21.63 Million
+5.25%
2021-12-31 CA$28.41 Million
≈ $20.55 Million
-16.58%
2020-12-31 CA$34.05 Million
≈ $24.63 Million
-19.46%
2019-12-31 CA$42.28 Million
≈ $30.59 Million
-59.25%
2018-12-31 CA$103.76 Million
≈ $75.06 Million
-19.52%
2017-12-31 CA$128.93 Million
≈ $93.27 Million
-39.96%
2016-12-31 CA$214.73 Million
≈ $155.33 Million
+910.15%
2015-12-31 CA$21.26 Million
≈ $15.38 Million
+224.01%
2014-12-31 CA$6.56 Million
≈ $4.75 Million
+81.85%
2013-12-31 CA$3.61 Million
≈ $2.61 Million
+5.37%
2012-12-31 CA$3.42 Million
≈ $2.48 Million
-27.82%
2011-12-31 CA$4.74 Million
≈ $3.43 Million
-8.32%
2010-12-31 CA$5.17 Million
≈ $3.74 Million
-13.38%
2009-12-31 CA$5.97 Million
≈ $4.32 Million
-37.45%
2008-12-31 CA$9.55 Million
≈ $6.91 Million
-72.56%
2007-12-31 CA$34.81 Million
≈ $25.18 Million
-41.78%
2006-12-31 CA$59.79 Million
≈ $43.25 Million
+54.03%
2005-12-31 CA$38.81 Million
≈ $28.08 Million
+285.33%
2004-12-31 CA$10.07 Million
≈ $7.29 Million
-55.00%
2003-12-31 CA$22.39 Million
≈ $16.19 Million
+322.69%
2002-12-31 CA$5.30 Million
≈ $3.83 Million
-43.52%
2001-12-31 CA$9.38 Million
≈ $6.78 Million
+112.05%
2000-12-31 CA$4.42 Million
≈ $3.20 Million
--

About Medicure Inc

V:MPH Canada Drug Manufacturers - Specialty & Generic
Market Cap
$31.10 Million
CA$43.00 Million CAD
Market Cap Rank
#24069 Global
#891 in Canada
Share Price
CA$4.12
Change (1 day)
-2.60%
52-Week Range
CA$0.90 - CA$4.44
All Time High
CA$10.58
About

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more